Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Public ClinicalTrials.gov record NCT04778397. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to compare the effectiveness of the study drugs, magrolimab in combination with azacitidine, versus venetoclax in combination with azacitidine in participants with previously untreated TP53 mutant acute myeloid leukemia (AML).
Study identification
- NCT ID
- NCT04778397
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 258 participants
Conditions and interventions
Conditions
Interventions
- Magrolimab Drug
- Venetoclax Drug
- Azacitidine Drug
- Cytarabine Drug
- Daunorubicin Drug
- Idarubicin Drug
- Steroidal Eye Drops Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2021 (Actual)
- Primary completion
- Mar 25, 2024 (Actual)
- Completion
- Mar 25, 2024 (Actual)
- Last update posted
- Feb 5, 2025
2021 – 2024
United States locations
- U.S. sites
- 36
- U.S. states
- 22
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | — |
| USC/ Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| UC Irvine Health | Orange | California | 92868 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| AdventHealth Orlando | Orlando | Florida | 32804 | — |
| Memorial Cancer Institute | Pembroke Pines | Florida | 33028 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Northwestern Memorial Hospital/Main Lab | Chicago | Illinois | 60611 | — |
| The University of Chicago Medical Centre | Chicago | Illinois | 60637 | — |
| University of Kansas Hospital | Fairway | Kansas | 66205 | — |
| University of Kentucky Medical Center | Lexington | Kentucky | 40536 | — |
| Tulane Medical center | New Orleans | Louisiana | 70112 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic Cancer Center Outpatient Pharmacy | Rochester | Minnesota | 55905 | — |
| MidAmerica Division, Inc., c/o Research Medical Center | Kansas City | Missouri | 64132 | — |
| SSM Health Saint Louis University Hospital | St Louis | Missouri | 63110 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Columbia University Medical Center - Herbert Irving Pavilion | New York | New York | 10032 | — |
| UNC Hospitals, The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Duke Blood Cancer Center | Durham | North Carolina | 27705 | — |
| The Ohio State University Wexner Medical Center/ James Cancer Hospital | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center - OU Health Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization | Philadelphia | Pennsylvania | 19107 | — |
| St. Francis Cancer Center | Greenville | South Carolina | 29607 | — |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29615 | — |
| Baylor College of Medicine Medical Center | Houston | Texas | 77030 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute ,The University of Utah | Salt Lake City | Utah | 84112 | — |
| Froedtert Hospital / Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 120 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04778397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04778397 live on ClinicalTrials.gov.